Additional file 2 of Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA

Additional file 2: Figure S1. Sample size of tissue samples (A) and plasma sample (B) in Phase I, Phase II and Phase III. The reused samples were showed in dot. Figure S2. Sample sizes of the key categories. Stage I (A) and CA19-9-negative PDAC (B) were shown. Figure S3. Overview of incremental feature selection of PDAC-specific MHB to build PandaX classifiers. Figure S4. Performance of PDAC-CP classifier in differentiating PDAC from CP plasma and covariate analysis. A. ROC of PDACatch classifying PDAC and CP plasma. B. PDACatch scores across different type of samples. In panel B, samples were labelled with cohorts (Train/Validation), pathological types (H: Healthy; CP: chronic pancreatitis) and clinical stages of PDAC (I, II, I-IIA and IIB-IV). For C-F, PDAC-CP classifier’s scores of PDAC and CP plasma samples were grouped by gender (A), age (B), tumour location (C) and tumour size (D). Wilcoxon rank sum test. ns: 0.05 < p